BioSpace News Archive

QuVa Pharma, Inc. announced that it is expanding its product label platform by adding 2D barcodes on all products, adhering to GS1 standards.

Vertex Announces U.S. FDA Approval for KALYDECO ® (ivacaftor) to Treat Eligible Infants With CF Ages 1 Month and Older.

Veracyte, Inc. (Nasdaq: VCYT) announced that data published in the journal Cancer show the ability of a novel gene expression signature to classify prostate cancer into distinct molecular subtypes that may inform which tumors are more likely to respond to different treatments.

Danaher Corporation announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the Bank of America Securities Health Care Conference in Las Vegas, Nevada on Wednesday, May 10, 2023 at 10:00 a.m. PT.

Taiho Oncology, Inc. and Servier today announced the publication of results from the pivotal Phase 3 SUNLIGHT* clinical trial of trifluridine/tipiracil (LONSURF®), alone or in combination with bevacizumab, in refractory metastatic colorectal cancer (mCRC) in the May 4, 2023, issue of the New England Journal of Medicine (NEJM).

Reneo Pharmaceuticals, Inc. announced the pricing of its previously announced underwritten public offering of 6,875,000 shares of its common stock at a public offering price of $8.00 per share for aggregate gross proceeds of approximately $55.0 million, before deducting underwriting discounts and commissions and offering expenses.

Vaxcyte, Inc. announced that Company management will participate in a fireside chat at the BofA Securities 2023 Health Care Conference in Las Vegas on Wednesday, May 10, 2023, at 5:20 p.m. ET / 2:20 p.m. PT.

Societal CDMO, Inc., a contract development and manufacturing organization dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, announced that the company will release financial results for the first quarter 2023 after the market close on Wednesday, May 10, 2023.

Cytokinetics, Incorporated announced that its Annual Meeting of Stockholders will be held on Wednesday, May 10, 2023 at 10:00 AM Pacific Time at the Company’s headquarters, 350 Oyster Point Blvd., South San Francisco, CA.

Myriad Genetics, Inc., a leader in genetic testing and precision medicine, announced financial results for its first quarter ended March 31, 2023.